A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 113
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CDAI
Long Form : CD activity index
No. Year Title Co-occurring Abbreviation
2020 Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. CD, CDEIS, CRP, FC
2020 Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis. CD, OR, TNF
2020 Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. CD, CI, CR, OR
2020 Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn's Disease: A Preliminary Study. CD, LOR, UST
2020 Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial. AEs, CD, SD
2020 Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers. CD, CDEIS, miRNAs
2020 Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment. CD, DD, GSS, IBS, IBS-SSS, UC
2020 Platelets can reflect the severity of Crohn's disease without the effect of anemia. CD, CRP, IBD, IDA, PLT, ROC, UC
2020 Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. CALM, CD, CM, ICER, QALYs, TC
10  2019 Characteristics of mucosa-associated gut microbiota during treatment in Crohn's disease. CD, HC, MDI
11  2019 Elevated Levels of Alveolar Nitric Oxide May Indicate Presence of Small Airway Inflammation in Patients with Inflammatory Bowel Disease. CANO, CD, eNO, FeNO, IBD, UC
12  2019 Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. CD, CI, SES-CD, TNF
13  2019 Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. CD, NMA, RCTs
14  2019 Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. CD, SES-CD
15  2018 A multicenter, prospective, observational study of the long-term outcomes of Crohn's disease patients under routine care management in Greece. CD, TNF
16  2018 Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. CD, CR-50, CRP, EOW
17  2018 Prediction of clinical outcomes in Crohn's disease by using confocal laser endomicroscopy: results from a prospective multicenter study. CD, CDEIS, CLE, CRP, RR
18  2018 Serum amyloid A level correlated with endoscopic findings in patients with Crohn's disease-Possible biomarker for evaluating mucosal healing. CD, MH, ROC, SAA, SES-CD
19  2018 The potential role of FDG PET-CT in the characterization of the activity of Crohn's disease, staging follow-up and prognosis estimation: a pilot study. CD, SES-CD
20  2018 The utility of food antigen test in the diagnosis of Crohn's disease and remission maintenance after exclusive enteral nutrition. CD, CRP, EEN, ESR
21  2018 Utility of video capsule endoscopy for longitudinal monitoringof Crohn's disease activity in the small bowel:aprospective study. CD, CE, CECDEIS, HBI, PGA, SES-CD
22  2017 CT Enterography for Surveillance of Anastomotic Recurrence within 12 Months of Bowel Resection in Patients with Crohn's Disease: An Observational Study Using an 8-Year Registry. CD, CTE
23  2017 Effect of Electro-Acupuncture and Moxibustion on Brain Connectivity in Patients with Crohn's Disease: A Resting-State fMRI Study. CD, DMN, IBDQ, MCC, rsFC
24  2017 Is Oxidative Stress Associated with Activation and Pathogenesis of Inflammatory Bowel Disease? CD, EAI, IBD, OSI, TAS, TOS, UC
25  2017 Oral mucosa lesions in patients with active Crohn’s disease - a prospective study. CD
26  2017 Possible undertreatment of women with Crohn disease in Poland. A subgroup analysis from a prospective multicenter study of patients on anti-tumor necrosis factor therapy. BMI, CD, TNF
27  2017 Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naive to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. CD, TNF-alpha
28  2016 Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease. CD, CRP, FC, hs
29  2016 Alterations in glutathione peroxidase and superoxide dismutase activities in plasma and saliva in relation to disease activity in patients with Crohn's disease. CD, GPx, ROS, SOD
30  2016 Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. ADA, CD
31  2016 Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease. BMI, CD, IFX, NRI
32  2016 Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease. ADRs, AEs, CD, CS
33  2016 Is ischemia modified albumin a disease activity marker for inflammatory bowel diseases? CD, EAI, IBD, IMA, UC
34  2016 Misdiagnosis and Mistherapy of Crohn's Disease as Intestinal Tuberculosis: Case Report and Literature Review. CD, ITB
35  2016 Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease. CD, CRP, EEN, miRNAs
36  2016 Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease. ADR, CD, TB, TNF-alpha
37  2015 A phase II study of laquinimod in Crohn's disease. AEs, CD, TF
38  2015 An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. CD, GMA
39  2015 Body Mass Index Is a Marker of Nutrition Preparation Sufficiency Before Surgery for Crohn's Disease From the Perspective of Intra-Abdominal Septic Complications: A Retrospective Cohort Study. BMI, CD, CI, IASCs, OR
40  2015 Effect of tumor necrosis factor-alpha antagonists on oxidative stress in patients with Crohn's disease. BAP, CD, d-ROM, m-OA, TNF
41  2015 Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. CD, CENTRAL, UC
42  2015 Impact of enteral nutrition on energy metabolism in patients with Crohn's disease. CD, CRP, EN, ESR, REE, SMM
43  2015 Prevalence of anemia and iron deficiency in Romanian patients with inflammatory bowel disease: a prospective multicenter study. CD, UC
44  2015 Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease Patients. CD, DC, IC
45  2015 Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study. CD
46  2015 Usefulness of C-reactive protein as a disease activity marker in Crohn's disease according to the location of disease. CD, CRP
47  2014 A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. CD, CDEIS, MSCs
48  2014 Bamboo joint-like appearance of the stomach: a stable endoscopic landmark for Crohn's disease regardless of anti-tumor necrosis factor alpha treatment. BJA, CD, SES-CD, TNF
49  2014 Biochemical markers and MR imaging findings as predictors of crohn disease activity in patients scanned by contrast-enhanced MR enterography. CD, CDEIS, CI, MR, OR
50  2014 Contrast-enhanced ultrasonography for the determination of Crohn's disease activity - preliminary experience. CD, CEUS, LDCTE, PE, RT, WiR
51  2014 Doppler ultrasound findings correlate with tissue vascularity and inflammation in surgical pathology specimens from patients with small intestinal Crohn's disease. CD, US
52  2014 Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. CD, TNF
53  2014 FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. CD, CDEIS, FDG, GCDAS, MAV, PET
54  2014 Intestinal wall thickness detected by multidetector spiral computed tomography enterography predicts the disease severity of Crohn's disease. CD, CRP, MSCTE, SES-CD
55  2014 Randomized controlled trial: moxibustion and acupuncture for the treatment of Crohn's disease. CD, CRP, Hgb
56  2013 Computed tomography enterography versus balloon-assisted enteroscopy for evaluation of small bowel lesions in Crohn's disease. CD, CTE
57  2013 Correlation between extraintestinal manifestations and clinical parameters with the histologic activity index in patients with inflammatory bowel diseases. CD, UC
58  2013 The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn's disease: A 5-year prospective cohort study. CD
59  2012 Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia. CD, CML, GMA
60  2012 Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease. ADA, anti-TNFalpha, CD, CRP, GMA, SES-CD
61  2012 Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. CD, CLA, IBDQ
62  2012 Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. CARD15, CD, IBD5, NOD2
63  2012 Current status of mesenchymal stem cell therapy and bone marrow transplantation in IBD. CD, HSCT, MSCs
64  2012 Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. CCFA, CD, IBD, IQR, MMAS, PROs, SCCAI, SD, SIBDQ, UC
65  2012 Factors associated with the loss of response to infliximab in patients with Crohn's disease. ANA, CD, CIC, GMA, IFX, LOR, sIL-2R
66  2012 Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity. CD, CICDA, MPI, ROC, US
67  2012 Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. AE, CD, CRP, IFX, IOIBD
68  2012 The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses. CD, CRP, GMA
69  2011 A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial. BMD, CD, DXA, ZOL
70  2011 Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. ACCESS, anti-TNF, CD, HBI, s.c
71  2011 Immunoregulatory effects of adsorptive granulocyte and monocyte apheresis in patients with drug refractory Crohn's disease. CD, GMA, TGF
72  2011 Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study. BMI, CD
73  2011 Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naive patients with Crohn's disease. CD, IFN, IFX, IL, TNF
74  2011 Peripheral Blood CD64 Levels Decrease in Crohn's Disease following Granulocyte and Monocyte Adsorptive Apheresis. CD, GMA
75  2011 [Comparison between staged surgery and one-stage surgery in active complex Crohn disease]. CD, CRP, ESR
76  2010 Association between tumor necrosis factor-alpha and Fc-gamma receptor polymorphisms with infliximab in Crohn's disease. CD, FcgammaR, IFX, TNF-alpha
77  2010 Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. CD, IBDQ, WPAI
78  2010 Clinical trial: the safety and short-term efficacy of recombinant cholera toxin B subunit in the treatment of active Crohn's disease. CD
79  2010 Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. ATI, CD, CRP, f-IFX, FP-EIA, GII, IFX, TNF
80  2010 Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn's disease. CD, EN
81  2010 Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease. 5-ASA, CD, GMA, IFX
82  2010 [Enteral nutritional therapy in Crohn disease complicated with incomplete intestinal obstruction]. CD, EN, PEG/J, TEN
83  2009 Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohn's disease. CD, CDUS, CEUS, US
84  2009 Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. CD, IL
85  2009 Sargramostim in patients with Crohn's disease: results of a phase 1-2 study. CD, s.c
86  2009 [Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease]. CD
87  2008 Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. CD, CI, WCE
88  2008 Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease. CD, IP, LMR
89  2008 Prevalence and clinical significance of sonographic evidence of mesenteric fat alterations in Crohn's disease. CD, OR
90  2008 Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. CD, EQ-VAS, IBDQ, MCS, PCS, SRMs, WPAI
91  2007 Chios mastic treatment of patients with active Crohn's disease. CD, CRP, IL-6, MCP-1, NRI, TAP, TNF-alpha
92  2007 Efficacy of T2 in active Crohn's disease: a prospective study report. CD, CRP, IL, TNF, TwHF
93  2007 Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. CD, PP
94  2006 A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. CD
95  2006 Clinically active Crohn's disease in the presence of a low C-reactive protein. CD, CRP
96  2006 Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. CD, CRP, hs-CRP, IBD, UC
97  2006 Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. CD, DAI, GMA, UC
98  2005 Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis. CRP, UC
99  2005 Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. CD
100  2005 Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. CD